Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Nov 29, 2022 5:21pm
202 Views
Post# 35137974

RE:RE:RE:Ever get the feeling that:

RE:RE:RE:Ever get the feeling that:I agree; it does seem like a stretch. I was thinking about AN today; they list as partners Roche, MSD aka Merck and ONC. Let us assume AN is not out of it.  Merck and Pfizer are together on BRACELET-1. Roche has the stellar GOBLET.

Let us imagine that Roche, & Pfizer/Merck get together and take an offer to ONC. The threesome would be an entity, and they could do more for patients as an entity. Specializing in their own areas of expertise but as a cohesive unit. if you will. Then there is AN to consider, and I am assuming they are still in, are currently in trials with Roche and MSD, and still wanting to continue the partnership with ONC I am betting.

The above is idle speculation, and perhaps they will do it the old fashioned way and bid.

Regardless of how it comes, if it comes, shareholders will be in a good seat.

Cheers

 
<< Previous
Bullboard Posts
Next >>